comprehensive -WSS

comprehensive

author：comprehensive 2025-08-06 04:47:40 - browse：54833

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

hotspot

WSS

JPM 2024: Nvidia claims we're in biological revolution. Are we?

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Risky weight loss products often used by teens globally, per study

Heart disease and mental health: A look at cardiac psychology

CRISPR gene editing developments we’re watching in 2024

Drinking less cuts risk of oral cavity, esophageal cancer: Report

explore

comprehensive

Wikipedia

How to save PrEP access — and even expand it

Three issues to watch in global health in 2024

State Dept. review finds Biden bears some blame for Afghanistan failures

How I ended up pumping milk in a bathroom stall at JPM 2024

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Virtual care provider acquires bankrupt Pear's prescription apps

Tori Bowie and the unacceptable rates of Black maternal death

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Trump demands the U.S. pay no more for drugs than other countries … again

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

Virtual care provider acquires bankrupt Pear's prescription apps

New Medicare drug pricing powers could soon be upended in court

HHS names first

The SUPPORT Act is critical to fighting the opioid crisis

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Medicare Advantage beneficiaries sue Humana over algorithm use

hotspot

focus

hotspot

leisure time